Buy Biogen, as stock looks 'too good to ignore,' Wells Fargo says

A Biogen facility in Cambridge, Massachusetts.
Brian Snyder | Reuters

Investors are underestimating a new Alzheimer's drug from Biogen and some of the company's other key businesses, according to Wells Fargo.

More In Street Calls

CNBC ProHere are Friday's biggest analyst calls of the day: Apple, FedEx, Coinbase, Honeywell, Micron & more
CNBC ProEnergy stocks are the best bet in the market right now, says JPMorgan
CNBC ProBank of America downgrades Micron, says recovery is 'unlikely' this year